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INTRODUCTION
In recent years, it has become clear that inflammatory re-
sponse and innate/adaptive immune response play a major 
role in the outcome of septic patients, with real difficulties 
in defining the most appropriate supportive treatment, 
particularly in patients with septic shock or persisting/re-
lapsing infections (Busani et al., 2016; Levy et al., 2003). 
Septic shock is a life-threatening condition characterized 
by severe hypotension and abnormalities in cellular me-
tabolism with very high mortality despite the appropriate 
therapy (Singer et al., 2016). Among the multiple immu-
nological effects, a significant decrease of serum level of 
IgM has been reported during septic shock, specifically 
in those cases progressing from severe sepsis into septic 
shock, with lower IgM levels among non-survivors (Giam-
arellos-Bourboulis et al., 2013). The combined presence of 
low levels of endogenous immunoglobulins IgG1, IgM and 




©2019 by EDIMES - Edizioni Internazionali Srl. All rights reserved
patients affected by severe sepsis or septic shock (Berme-
jo-Martin et al., 2014). In this context, there is a rational to 
discuss the use of adjunctive therapies, in addition to ap-
propriate antimicrobials and cardiovascular support, such 
as the administration of intravenous immunoglobulins 
and, specifically, IgM-enriched immunoglobulins (IgM). 
Since the official indication in several countries, includ-
ing Italy, is the supportive treatment of patients with acute 
severe bacterial infections, it was felt that a simple tool 
could be helpful in guiding the administration of IgM. The 
aim of this multidisciplinary consensus was to develop a 
score for the identification of patients with bacterial in-
fection who may best benefit by an early administration 
of IgM.
METHODS
Position Paper Procedure 
The process was managed by a multidisciplinary panel, 
including specialists in Anesthesiology and Critical Care, 
Infectious Diseases, Pulmonology, Hematology and Clini-
cal Microbiology highly experienced in research and in the 
clinical management of patients with sepsis. A multistep 
process, with review of evidence, panel discussion and 
proposal of a clinical score or practical tool to support the 
IgM administration was adopted. 
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SUMMARY
IgM-enriched immunoglobulins (IgM) may be useful in patients with severe acute bacterial infections. 
The evidence for the administration of IgM is not extensive and a definitive consensus has never been 
reached on its best use in patients with acute infections as well as in critically ill patients. However, the 
official indication in several countries, including Italy, is quite wide and mainly refers to supportive treat-
ment of patients with acute severe bacterial infections.
A multidisciplinary meeting of Italian Experts in Infectious Diseases, Anesthesia and Critical Care, Pneu-
mology, Microbiology and Oncohaematology aimed to produce a statement on the best practical method-
ological score that could improve the use of IgM in patients with different infections, variable severity of 
disease and etiology. The Expert Panel reviewed the literature and the available guidelines, discussed the 
experience and eventually proposed to adapt the PIRO score to the practical methodological needs of a 
simple tool that could guide the administration of IgM.
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The process was conducted in May 2018 and the opinions 
of the experts about IgM use in severe bacterial infections 
were discussed according to the literature and existing 
guidelines. The Experts were then invited to share their 
opinions based on their clinical experiences. Thereafter, 
a critical discussion and a comprehensive review of the 
literature was promoted. A general consensus was consid-
ered achieved if the level of agreement was ≥75%. 
After extensive discussion amongst the experts, the PIRO 
concept was proposed as a practical tool to support the 
evidence for IgM-IG administration. In 2001, the Inter-
national Sepsis Definitions Conference proposed a new, 
sophisticated, but more conceptual way of looking at 
sepsis syndrome: predisposition, infection (or insult), re-
sponse and organ dysfunction score, also called “PIRO.” 
The PIRO concept of classification scheme for sepsis in-
cludes predisposing condition, nature and extent of insult, 
nature and magnitude of host response, pattern and de-
gree of organ dysfunction (Levy et al., 2003). As opposed 
to the usual staging, based mainly on the severity of organ 
dysfunctions (i.e., sepsis) and metabolic involvement (i.e., 
septic shock), the PIRO concept takes into account many 
important aspects of the management of patients with in-
fections, closely related to their risk of mortality (Rello et 
al., 2009; Cardoso et al., 2013; Chen et al., 2013). The panel 
decided to use the PIRO as a supportive tool for the iden-
tification of patients to be treated with IgM.
REVIEW OF THE EVIDENCE
Sepsis and septic shock
The effects of IgM have been investigated in different set-
tings and in different populations, especially in Surgery 
and Intensive Care Units (ICUs). A Cochrane review on 43 
studies evaluated the effects of IgM as adjunctive therapy 
in patients with bacterial sepsis or septic shock based on 
mortality, bacteriological failures and duration of stay in 
hospital. Unfortunately, clinical heterogeneity prevented a 
pooled analysis of polyclonal and monoclonal intravenous 
immunoglobulins (IVIG) and the reaching of a global sta-
tistical significance. Moreover, a significant reduction of 
mortality in adults with sepsis compared to placebo or 
no intervention was observed in a subgroup analysis of 
10 polyclonal IVIG trials and seven trials on IgM prepa-
ration (RR 0.81), but not in trials at low risk. The authors 
concluded that polyclonal IVIG reduced mortality among 
adults with sepsis, but the evidence for IgM preparation 
is still insufficient to support a robust conclusion of ben-
efit, even if the mortality reduction was about 20% (Ale-
jandria et al., 2013). The results of this review confirmed 
those reported by the metanalysis from Kreymann et al 
(Kreymann et al., 2007). A more recent retrospective study 
evaluated the efficacy of early therapy with IgM (adminis-
tered within 24 hours after shock onset) on 30-day mor-
tality rate in ICU patients with septic shock. As many as 
92 out of 168 (54.8%) patients included in the study re-
ceived IgM therapy. The results showed a 21.1% reduction 
of the 30-day mortality rate in the group treated with IgM 
compared to the control group (p<0.05). Early adjunctive 
therapy with IgM can be associated with a survival benefit 
in patients with septic shock (Cavazzuti et al., 2014). Fi-
nally, the meta-analysis of 18 randomized clinical trials by 
Busani et al. evaluated the clinical effectiveness of immu-
noglobulins use in adult septic patients. According to this 
review, the administration of IgM may reduce the mortal-
ity risk of septic patients (odds ratio 0.50), in spite of the 
bias of these studies (low quality, heterogeneous dosing 
regimens and type of Ig preparations, different control in-
terventions) (Busani et al., 2016).
A recent phase II trial (CIGMA trial) evaluated the safety 
and efficacy of a new product (i.e., trimodulin) contain-
ing a higher proportion (23%) of IgM than the standard 
preparation (12%) as adjunctive therapy in patients with 
severe community acquired pneumonia (sCAP). Although 
the primary end-point (i.e., significant reduction of venti-
lator free days) was not achieved, the study confirmed the 
safety of the product and indicated a potential improve-
ment in survival of patients with low IgM and/or elevated 
reactive protein C plasma levels at enrollment (Welte T et 
al., 2018). A phase III trial aimed at evaluating the effects 
of trimodulin on mortality of patients with sCAP is under-
way.
Timing of administration 
An important issue is the appropriate timing of IgM ad-
ministration. Overwhelming septic shock caused by Neis-
seria meningitidis and Streptococcus pneumoniae is a spe-
cific phenotype of hyperacute sepsis, occurring in young 
and healthy people, whose associated mortality has re-
mained unchanged even after remarkable improvements 
in patient identification and timely antibiotic therapy in 
many countries in the last decades (Giraud et al., 1991). 
Berlot et al. retrospectively evaluated the relationship be-
tween the timing of administration of IgM enriched im-
munoglobulins and the outcome of 129 adult ICU patients 
with severe sepsis and septic shock. The results demon-
strated that the timing of IVIG administration is essential, 
with a linear relationship in terms of survival (survivors 
were treated significantly earlier than non-survivors: 23 
vs 63 hours, p<.05) and an increase of mortality risk by 
0.7% for each hour of delay. The authors concluded that 
the efficacy of IgM is time-dependent and is higher in the 
early phases of severe sepsis and/or septic shock (Berlot et 
al., 2012). These data were further confirmed in a larger 
population of similar patients, including for the subgroup 
of patients with septic shock by MDR pathogens (Berlot et 
al., 2018).
A specific topic related to the timing of administration is 
the kinetics of circulating IgM during the different stages 
of sepsis and its relationship with final outcome, which 
was the objective of the prospective multicenter study 
performed by Giamarellos et al. on 332 critically ill pa-
tients (83 of whom progressed to more severe stages of 
sepsis; 30 patients with severe sepsis progressed to shock 
and IgM was monitored daily for seven consecutive days). 
IgM levels decreased in septic shock compared to patients 
with systemic inflammatory response syndrome (SIRS) 
and patients with severe sepsis, but only when patients 
deteriorated from severe sepsis to septic shock. Moreover, 
the production of IgM in peripheral blood mononuclear 
cells was significantly lower during sepsis compared with 
healthy controls (Giamarellos-Bourboulis et al., 2013). 
These results may clearly indicate an important role of 
IgM levels on the patients’ outcome. 
Severe Infections by Multi-drug resistant bacteria (MDR)
Patients with sepsis and septic shock by opportunistic 
MDR bacteria are at very high risk of death despite ad-
equate antibiotic therapy. This seems to be caused by 
the severe dysfunction of the immune system (i.e., im-
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mune-paralysis) occurring in many patients after sepsis, 
trauma or extensive surgery. In this context, IgM may 
have a therapeutic role as supportive immune-therapy. 
The available data demonstrate a positive effect of IgM 
on the mortality rate of patients with MDR infections 
(Berlot et al., 2018). A recently published retrospective 
study analyzed the risk factors for 30-day mortality and 
the impact of sepsis management in 94 patients with sep-
tic shock caused by MDR bacteria admitted to the ICU 
of Modena University Hospital during a 6-year period. 
Among all the therapeutic interventions applied to pa-
tients during the ICU stay, only the administration of IgM 
was significantly associated with survival. The multivar-
iate adjusted analysis showed that an active cancer and 
Acinetobacter baumannii infections were related to an in-
creased risk of 30-day mortality and that IgM had a pro-
tective role (Busani et al., 2017). A retrospective analysis 
of a large prospective multicenter cohort study evaluated 
the outcomes (28-day mortality rate, mortality by MDR 
pathogens) of 100 ICU patients with microbiological-
ly confirmed severe infections by MDR pathogens after 
adjunctive treatment with IgM versus a control group 
(n=100 matched for stage of sepsis, source of infection, 
appropriateness of antimicrobials and co-morbidities). 
Mortality was significantly reduced in the group treated 
with IgM (odds ratio 0.46; p=0.011); mortality in patients 
infected by MDR Gram-negative bacteria was also higher 
in comparators respect to the group treated with IgM-
IG (62.5% vs. 38.5%, respectively; p=0.008) (Giamarel-
los-Bourboulis et al., 2016).
BENEFIT OF IGM USE IN CLINICAL 
PRACTICE: THE TO-PIRO SCORE 
The administration of intravenous immunoglobulins 
(IVIG) represents a possible additional supportive treat-
ment for the management of acute severe bacterial infec-
tions, even though a general consensus based on scientific 
evidence is still lacking. A meta-analysis of 15 trials on 
1,492 adult patients with sepsis or septic shock showed 
that IVIG had a significant effect on mortality (relative re-
duction of the risk of death - RR: 0.79, p≤.0003), with a 
trend in favor of immunoglobulin preparations enriched 
with IgA and IgM (RR=0.66 versus 0.85 of preparations 
with IgG only) (Kreymann KG et al., 2007). Although the 
results of further metanalysis confirmed the possible ben-
eficial effects of the use of IVIG in septic patients (Busani 
et al., 2016), the last edition of the Surviving Sepsis Cam-
paign Guidelines did not find clear evidence to support 
its administration (Rodhes et al., 2017). The major issues 
raised were the high heterogeneity of available studies in 
terms of patient populations, type and dose of IVIG used, 
age (children or adults), underlying infections and selec-
tion of control groups. Indeed, the use of IVIG in patients 
with sepsis and/or specific infections such as necrotiz-
ing fasciitis or meningitis was only advised by other ev-
idenced-based guidelines (Sartelli et al., 2014; Wilkins et 
al., 2017), widely used in many countries.  
The high heterogeneity of immune-inflammatory re-
sponse makes it implausible that a single supportive thera-
py might be effective in all patient populations with sepsis. 
Therefore, it is crucial to identify patient phenotypes that 
can receive special advantage from each specific adjunc-
tive therapy, especially with the widely approved indica-
tions of IgM. Many papers have been published over the 
last 30 years on the use of IgM, mainly on IgM prepara-
tion, in the treatment of the sepsis syndrome (Kakoullis et 
al., 2018) but the evidence of clinical benefit is still incon-
clusive (Rodhes A et al., 2017). The practical question is 
when and how to administer IgM in the supportive treat-
ment of acute severe bacterial infections, a complex and 
challenging clinical phenotype.
A specific TO-PIRO score was proposed and discussed 
with a multi-step review process: literature evidences, 
pathophysiological reasoning and personal clinical experi-
ence. The role of clinical, microbiological and biochemical 
parameters on the efficacy of IgM were evaluated and the 
following criteria were considered for the development of 
TO-PIRO score (Table 1):
1) The predisposition (P) components of PIRO were: 
cancer, MDR pathogens or candida colonization, neu-
tropenia, immunosuppressive therapy (steroids, mon-
oclonal antibodies, mycophenolate, cyclosporine), al-
logenic stem cell transplant, splenectomy;
Table 1 - Evaluation criteria of the TO-PIRO score.
Items Criteria Score
Predisposition • Uncontrolled cancer
• Colonization by MDR bacteria and/or candida 
• Neutropenia or immunosuppressive drugs (monoclonal/steroids/micophenolate/cyclosporin) 




Insult • Necrotizing fasciitis, invasive meningococcal/ pneumococcal diseases,  
Streptococcus pyogenes; CA-MRSA 





Response • Leucocytes < 600/ul
• IgM < 60 mg/dl
• PCT > 10 ng/l and CRP >20 mg/dl
• PCT > 100 ng/l or endotoxin > 0.6 or IL-6>1000 pg/ml or adrenomedullin > 4 nm/l  
or presepsin 1400 ng/l






Organ • Septic shock
• Sepsis with ≥ 1 organ failure




CA-MRSA, methicillin-resistant Staphylococcus aureus; CRP, C-reactive protein; IgM, immunoglobulins M; IL, interleukin; MDR, multi-drug resistant; PCT, procalcitonin.
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confirmed by large databases and by application in daily 
clinical practice.
In conclusion, several aspects of the role of IgM therapy 
were reviewed, evaluated and addressed. While waiting 
for future large prospective trials clarifying the role of 
Ig therapy in sepsis (Kakoullis L et al., 2018), the experts 
concluded that IgM administration may greatly bene-
fit from a simple practical tool to guide its use in severe 
bacterial infections. The TO-PIRO score may be useful to 
appropriately identify patients who may best benefit from 
IgM treatment.
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The Consensus assigned a score ranging from 1 to 5 (1 = 
not relevant; 5 = very important) to each criterion of the 
TO-PIRO score (Table 2). After the first proposal, the TO-
PIRO score was further discussed and then further mod-
ified and validated in a plenary session the day after the 
Consensus meeting. 
According to the result of the TO-PIRO score, the Ex-
pert Panel identified three levels of support: IgM ad-
ministration considered, recommended or strongly 
recommended (Table 2). A TO-PIRO score <5 indicates 
an uncertain benefit from the use of IgM: individual as-
sessment should be performed according to guidelines. 
A TO-PIRO score in the range of 6-10 suggests a po-
tential benefit of IgM, initiated after antibiotic thera-
py and within 24 hours after identification of infection. 
Finally, when the TO-PIRO score is >10, the use of IgM 
is strongly recommended within 6 hours after identifi-
cation because the therapy may significantly decrease 
the mortality risk.
CONCLUSION AND FUTURE PERSPECTIVES
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this purpose, the TO-PIRO score, based on the PIRO con-
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TO-PIRO score has limitations and should be considered 
as a useful guide to practically translate the official indi-
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who may benefit from IgM therapy should be urgently 
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TO-PIRO SCORE Recommendation Timing
TO-PIRO ≤ 5 The use of IgM may be beneficial according to clinical scenario –
TO-PIRO > 5-10 The use of IgM is suggested: evidence suggest a potential benefit  
in these patients 
Administered within 24h from clinical 
presentation 
TO-PIRO >10 Use of IgM is strongly recommended: evidence showed  
a low mortality rate associated to the use of IgM
As soon as possible  
and within 6 h
IgM, immunoglobulins M.
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